ADXS Advaxis Inc. featured news, full reports, and detailed charts
Advaxis Inc. (ADXS/ADXS.OB) Wrap Up:
Advaxis, Inc., a development stage biotechnology company, engages in the research and development of new cancer-fighting techniques. It develops cancer vaccines targeting cervical, breast, prostate, ovarian, lung, and other cancers. The company’s products in development include Lovaxin C, a Phase I/II trial product to treat cervical intraepithelial neoplasia, cervical cancer, and head and neck cancer; Lovaxin P, a preclinical stage product for prostate cancer; and Lovaxin B, a preclinical stage product to treat breast cancer. Advaxis has strategic collaboration with Cobra Biomanufacturing PLC for manufacturing cervical cancer vaccine. The company was founded in 2002 and is based in North Bru...Advaxis Inc. (ADXS:OTC Bulletin Board Market)
Snapshot of Advaxis Inc. (ADXS)
|
OPEN
$0.12
|
PREVIOUS CLOSE
$0.12
|
|
|
DAY HIGH
$0.12
|
DAY LOW
$0.11
|
|
|
52 WEEK HIGH
05/29/09 - $0.21
|
52 WEEK LOW
12/8/08 - $0.01
|
|
|
MARKET CAP
12.8M
|
AVERAGE VOLUME 3 mo
376.0K
|
|
|
DILUTED EPS TTM
--
|
SHARES OUTSTANDING
115.6M
|
|
|
ADXS Does Not Pay Dividends
|
P/E TTM
NM
|
|
| K = Thousands M = Millions B = Billions | ||
ADXS Top Compensated Officers
Executives, Board Directors
Key developments for Advaxis Inc. (ADXS)
Advaxis Inc. - Conference Presentation Calls
Advaxis Inc. - Conference Presentation Calls
Advaxis Inc. has received approval from the New England Institutional Review Board (IRB) to enroll the first patient in a Phase II clinical trial of cervical dysplasia (cervical intraepithelial neoplasia or CIN). The study will be a blinded, randomized comparison of ADXS11-001 versus placebo for the treatment of cervical dysplasia. In this Phase II clinical trial, patients will receive three administrations of ADXS11-001 at monthly intervals. Six months after receiving their first dose, they will receive the standard of care for the treatment of their disease, which is surgery. Efficacy will be determined by comparing pre-treatment biopsy samples with surgical tissue samples. The experimental protocol calls for thirty patients in each group to be treated, for a total of one hundred, twenty patients. ADXS11-001 dosage groups include two doses that are lower than previously administered (5.0 x107 and 3.3 x108 cfu) and one at the lowest dose administered in Phase I (1.0x109 cfu).
ADXS Competitors
| Company | Last | Change |
| Antigenics Inc | $0.90 USD | -0.0599 |
| Cerus Corporation | $2.00 USD | -0.03 |
| Dendreon Corp | $28.01 USD | -0.04 |
| Generex Biotechnology Corp | $0.50 USD | -0.01 |
| Vical Inc | $3.07 USD | -0.11 |
| Market data is delayed at least 20 minutes. | ||
Industry Analysis
| Valuation | ADXS | Industry Range |
| Price/Earnings | NM | Not Meaningful |
| Price/Sales | NM | Not Meaningful |
| Price/Book | NM | Not Meaningful |
| Price/Cash Flow | NM | Not Meaningful |
| TEV/Sales | NM | Not Meaningful |
|
ADXS |
||
ADXS transactions
| Type Date |
Target |
|
Private Placement
October 7, 2009 |
-- |
|
Private Placement
September 24, 2009 |
-- |
|
Private Placement
June 17, 2009 |
-- |